Latest News
19Feb 19
Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26
REDWOOD CITY, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019…
read more14Feb 19
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of…
read more06Feb 19
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
REDWOOD CITY, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron,…
read more04Feb 19
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
REDWOOD CITY, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install…
read more08Nov 18
Codexis Reports Third Quarter 2018 Financial Results
Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) —…
read more